Literature DB >> 21907760

Selective liver X receptor modulators (SLiMs): what use in human health?

Emilie Viennois1, Kevin Mouzat, Julie Dufour, Laurent Morel, Jean-Marc Lobaccaro, Silvère Baron.   

Abstract

Liver X receptors (LXR) are members of the nuclear receptor family. As activated transcription factors, their putative association with human diseases makes them promising pharmacological targets because of the large potential to develop ligands. LXR are mainly considered as intracellular cholesterol "sensors" whose activation leads to decreased plasma cholesterol. They also modulate numerous physiological functions: fatty acid synthesis and metabolism, glucose homeostasis, steroidogenesis, immunity, and neurological homeostasis. LXR-deficiency in mouse results in several phenotypes mimicking pathological conditions in humans. This review will be focused on the various natural and synthetic LXR agonists and antagonists. Putative clinical targets including atherosclerosis, diabetes, Alzheimer's disease, skin disorders, and cancer will be covered. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21907760     DOI: 10.1016/j.mce.2011.08.036

Source DB:  PubMed          Journal:  Mol Cell Endocrinol        ISSN: 0303-7207            Impact factor:   4.102


  32 in total

1.  Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis.

Authors:  Colin A Flaveny; Kristine Griffett; Bahaa El-Dien M El-Gendy; Melissa Kazantzis; Monideepa Sengupta; Antonio L Amelio; Arindam Chatterjee; John Walker; Laura A Solt; Theodore M Kamenecka; Thomas P Burris
Journal:  Cancer Cell       Date:  2015-06-25       Impact factor: 31.743

Review 2.  Targeting liver X receptors in cancer therapeutics.

Authors:  Chin-Yo Lin; Jan-Åke Gustafsson
Journal:  Nat Rev Cancer       Date:  2015-03-19       Impact factor: 60.716

3.  Liver X receptors as potential targets for cancer therapeutics.

Authors:  Xiaoli Ju; Pan Huang; Miao Chen; Qiang Wang
Journal:  Oncol Lett       Date:  2017-10-23       Impact factor: 2.967

Review 4.  Cellular fatty acid metabolism and cancer.

Authors:  Erin Currie; Almut Schulze; Rudolf Zechner; Tobias C Walther; Robert V Farese
Journal:  Cell Metab       Date:  2013-06-20       Impact factor: 27.287

5.  The oxysterol receptor LXRβ protects against DSS- and TNBS-induced colitis in mice.

Authors:  T Jakobsson; L-L Vedin; T Hassan; N Venteclef; D Greco; M D'Amato; E Treuter; J-Å Gustafsson; K R Steffensen
Journal:  Mucosal Immunol       Date:  2014-05-07       Impact factor: 7.313

6.  Pan-cancer analyses of the nuclear receptor superfamily.

Authors:  Mark D Long; Moray J Campbell
Journal:  Nucl Receptor Res       Date:  2015-12-15

7.  LXR, prostate cancer and cholesterol: the Good, the Bad and the Ugly.

Authors:  Hugues de Boussac; Aurélien Jc Pommier; Julie Dufour; Amalia Trousson; Françoise Caira; David H Volle; Silvère Baron; Jean-Marc A Lobaccaro
Journal:  Am J Cancer Res       Date:  2013-01-18       Impact factor: 6.166

Review 8.  Liver X Receptors and female reproduction: when cholesterol meets fertility!

Authors:  J M A Lobaccaro; D Gallot; S Lumbroso; K Mouzat
Journal:  J Endocrinol Invest       Date:  2012-11-27       Impact factor: 4.256

9.  Oleic acid modulates mRNA expression of liver X receptor (LXR) and its target genes ABCA1 and SREBP1c in human neutrophils.

Authors:  María Edith Reyes-Quiroz; Gonzalo Alba; Javier Saenz; Consuelo Santa-María; Isabel Geniz; Juan Jiménez; Remedios Ramírez; José Martín-Nieto; Elizabeth Pintado; Francisco Sobrino
Journal:  Eur J Nutr       Date:  2014-04-11       Impact factor: 5.614

Review 10.  Nuclear hormone receptor functions in keratinocyte and melanocyte homeostasis, epidermal carcinogenesis and melanomagenesis.

Authors:  Stephen Hyter; Arup K Indra
Journal:  FEBS Lett       Date:  2013-02-05       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.